Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype

Colorectal cancers (CRC) can be classified into four consensus molecular subtypes (CMS), among which CMS1 has the best prognosis, contrasting with CMS4 that has the worst outcome. CMS4 CRC is notoriously resistant against therapeutic interventions, as demonstrated by preclinical studies and retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jiayin, Tian, Ai-Ling, Pan, Hui, Sauvat, Allan, Leduc, Marion, Liu, Peng, Zhao, Liwei, Zhang, Shuai, Chen, Hui, Taly, Valérie, Laurent-Puig, Pierre, Senovilla, Laura, Li, Yingqiu, Kroemer, Guido, Kepp, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531384/
https://www.ncbi.nlm.nih.gov/pubmed/34675191
http://dx.doi.org/10.1038/s41419-021-04270-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531384/
https://www.ncbi.nlm.nih.gov/pubmed/34675191
http://dx.doi.org/10.1038/s41419-021-04270-x

Ejemplares similares